亿帆医药: 第九届董事会第一次（临时）会议决议公告

Group 1 - The company held its second extraordinary shareholders' meeting on September 5, 2025, where a new board of directors was elected, consisting of 3 non-independent directors, 2 independent directors, and 1 employee representative director [1][2] - The first meeting of the newly elected board was convened on the same day, with all 6 directors present, and was chaired by Mr. Cheng Xianfeng [1][2] - Mr. Cheng Xianfeng was elected as the chairman of the ninth board of directors, with a term of three years from the date of the meeting [1][2] Group 2 - The board approved the appointment of senior management, including the reappointment of Mr. Cheng Xianfeng as president and the appointment of Mr. Feng Dexi as senior vice president and board secretary [2][3] - Other appointments included Mr. Wang Feng, Ms. Geng Yuhong, and Ms. Qian Liping as executive vice presidents, and Mr. Zhang Dawai as vice president and CFO, all with a term of three years [2][3] Group 3 - The board expressed gratitude to the outgoing directors, supervisors, and senior management for their contributions during their tenure [3][4] - The independent directors Cheng Genhong and Liu Hongquan, along with other members of the eighth board, completed their terms and will not hold any other positions in the company [3][4] Group 4 - The company’s audit committee will assume the responsibilities of the supervisory board as per legal requirements, following the completion of the eighth board's term [3][4] - The company has ensured compliance with relevant laws and regulations regarding the appointment and responsibilities of its directors and management [3][4]